Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 9:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adults Clear all
Recruiting Not applicable Interventional

Up-2 Study: Cognitively Engaging Walking Exercise and Neuromodulation to Enhance Brain Function in Older Adults

NCT05830942
View directory record Official record
Conditions
Cognitive Dysfunction, Mobility Limitation, Frail Elderly
Interventions
Walking Exercise, Prefrontal Active tDCS, Prefrontal Sham tDCS
Behavioral · Device
Lead sponsor
University of Florida
Other
Eligibility
65 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 17, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

NCT04008186
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
Omaveloxolone, Midazolam oral solution, Repaglinide 1 MG, MetFORMIN 500 Mg Oral Tablet, Rosuvastatin, Digoxin tablet, Gemfibrozil Tablets, Itraconazole capsule, Verapamil Pill
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 17, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

RN624 In Adult Patients With Chronic Low Back Pain

NCT00584870
View directory record Official record
Conditions
Low Back Pain
Interventions
Naproxen, Placebo, PF-04383119 (RN624)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
38
States / cities
Anniston, Alabama • Birmingham, Alabama • Chandler, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 17, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy

NCT01821118
View directory record Official record
Conditions
Cerebral Amyloid Angiopathy
Interventions
Ponezumab, placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • Charlestown, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 17, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma

NCT02259010
View directory record Official record
Conditions
Advanced Solid Tumors, Relapsed/Refractory Lymphoma
Interventions
Alisertib, Itraconazole
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
St Louis, Missouri • Oklahoma City, Oklahoma • Germantown, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Sep 17, 2026, 9:40 AM EDT
Completed Phase 1 Interventional

A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS

NCT03573310
View directory record Official record
Conditions
Neoplasms, Solid Tumor, Adult, Non-Hodgkin Lymphoma, Myelodysplastic Syndromes
Interventions
JNJ-64619178
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Sarasota, Florida • Boston, Massachusetts • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 17, 2026, 9:40 AM EDT
Completed Phase 1 Interventional

Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation

NCT03483324
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes, Other Acute Leukemias
Interventions
Unmanipulated Umbilical Cord Blood (UCB), AB-110
Biological
Lead sponsor
Angiocrine Bioscience
Industry
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Duarte, California • Aurora, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Sep 17, 2026, 9:40 AM EDT
Completed Phase 3 Interventional

Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder

NCT00277823
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
DVS-SR 50 mg, DVS-SR 100 mg, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Beverly Hills, California • Northridge, California • Farmington, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Sep 17, 2026, 9:40 AM EDT
Completed Not applicable Interventional

Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy

NCT01519596
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
quality-of-life assessment, counseling intervention, exercise intervention, educational intervention, standard follow-up care
Procedure · Other · Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2019 · Synced Sep 17, 2026, 9:40 AM EDT
Recruiting Phase 2 Interventional

RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

NCT06798896
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
SPN-817, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Port Charlotte, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 17, 2026, 9:40 AM EDT
Not yet recruiting Phase 2 Interventional

Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

NCT07689188
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Roflumilast 0.3% topical foam
Drug
Lead sponsor
Harrison Dermatology
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Missouri City, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 17, 2026, 9:40 AM EDT
Completed Phase 1 Interventional

NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

NCT03164603
View directory record Official record
Conditions
Solid Tumor
Interventions
NLG802
Drug
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Gainesville, Florida • St Louis, Missouri • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Sep 17, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability and Food Effect Study of CVN424

NCT05635461
View directory record Official record
Conditions
Parkinson's Disease
Interventions
CVN424
Drug
Lead sponsor
Cerevance Beta, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 17, 2026, 9:40 AM EDT
Recruiting Not applicable Interventional

Adapting, Implementing and Evaluating the Effectiveness of HARP for People With Disabilities

NCT07033897
View directory record Official record
Conditions
Disabilities Physical, Falls, Fall Prevention, Adults
Interventions
Adapted HARP
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
45 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 17, 2026, 9:40 AM EDT
Not listed Phase 1Phase 2 Interventional

Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00006460
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
hyperbaric oxygen, radiation therapy
Drug · Radiation
Lead sponsor
Barrett Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Sep 17, 2026, 9:40 AM EDT
Completed No phase listed Observational

Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia

NCT00897182
View directory record Official record
Conditions
Leukemia
Interventions
microarray analysis, polymerase chain reaction
Genetic
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Fort Wayne, Indiana • Goldsboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2016 · Synced Sep 17, 2026, 9:40 AM EDT
Enrolling by invitation Phase 2 Interventional

Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Adults

NCT03675724
View directory record Official record
Conditions
Frail Elderly Syndrome
Interventions
Fisetin, Placebo oral capsule
Dietary Supplement · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
70 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 17, 2026, 9:40 AM EDT
Terminated Phase 1 Interventional

A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

NCT06364696
View directory record Official record
Conditions
Solid Tumor
Interventions
ASP4396
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Westwood, Kansas • Grand Rapids, Michigan • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 17, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis

NCT02780388
View directory record Official record
Conditions
Adult Onset Rheumatoid Arthritis
Interventions
VIB4920, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Anniston, Alabama • DeBary, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 17, 2026, 9:40 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial

NCT07227103
View directory record Official record
Conditions
Treatment Resistant Depression, Treatment Resistant Depression (TRD)
Interventions
Neuronavigated robotic-enabled TMS, NRX-101, Sham TMS, Oral Placebo
Device · Drug
Lead sponsor
NeuroRx, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Sarasota, Florida • West Palm Beach, Florida • Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 17, 2026, 9:40 AM EDT
Terminated Phase 1 Interventional

A JZP341 Study in Adult Participants With Advanced or Metastatic Solid Tumors

NCT05631327
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
JZP341
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Denver, Colorado • Sarasota, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced Sep 17, 2026, 9:40 AM EDT
Terminated Phase 1 Interventional

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

NCT02468661
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
INC280 single agent, erlotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 17, 2026, 9:40 AM EDT
Completed No phase listed Observational

Autoimmunity in Neurologic Complications of Celiac Disease

NCT00692861
View directory record Official record
Conditions
Ataxia
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 17, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333

NCT00768690
View directory record Official record
Conditions
HCV Infection
Interventions
ABT-333, ketoconazole, placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Waukegan, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Sep 17, 2026, 9:40 AM EDT